Much progress had been made during the last decade in the use of high- dose chemotherapy and autologous bone marrow transplantation (ABMT) for lymphoid malignancies; however, the most optimal timing, best preparative regimen, and best hematopoietic rescue source for transplantation have not been identified. This article outlines various studies using high-dose therapy and ABMT for lymphoid malignancies at institutions throughout the world. Furthermore, the use of alternative hematopoietic sources such as autologous peripheral stem cells and the use of hematopoietic growth factors with transplantation for non-Hodgkin's lymphomas also are discussed.
|Original language||English (US)|
|Number of pages||14|
|Journal||Hematology/Oncology Clinics of North America|
|State||Published - Jan 1 1993|
ASJC Scopus subject areas